{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Potential therapeutic effects of oral bisphosphonates on the intestine.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Pazianas M. and Russell RGG., (2011), Ann n y acad sci, 1240, E19 - E25

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Bisphosphonates: the first 40 years.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Russell RGG., (2011), Bone, 49, 2 - 19

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Foreword: bisphosphonates.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Burr D. and Russell G., (2011), Bone, 49

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Sugiyama T. et al, (2011), Bone, 49, 133 - 139

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n The relationship between the chemistry and biological activity of the bisphosphonates.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Ebetino FH. et al, (2011), Bone, 49, 20 - 33

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Alendronate and ibandronate affect osteoclast formation and size differently from risedronate and zoledronate\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Mabilleau G. et al, (2011), Bone, 48, S220 - S220

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n The risk of oesophageal and gastric cancer incidence and mortality in alendronate users: National cohort study\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Abrahamsen B. et al, (2011), Bone, 48, S74 - S74

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Denosumab and bisphosphonates: different mechanisms of action and effects.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Baron R. et al, (2011), Bone, 48, 677 - 692

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Artz JD. et al, (2011), J biol chem, 286, 3315 - 3322

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Atrial fibrillation and the use of oral bisphosphonates.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Pazianas M. et al, (2011), Ther clin risk manag, 7, 131 - 144

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Adachi JD. et al, (2011), Ther clin risk manag, 7, 181 - 198

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n FORTY YEARS OF BISPHOSPHONATES\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Russell G., (2010), Osteoporosis international, 21, S445 - S445

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Pazianas M. et al, (2010), Ther clin risk manag, 6, 325 - 343

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Pazianas M. et al, (2010), Osteoporosis international, 21, 82 - 82

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Fu K. et al, (2010), J biomed mater res a, 92, 1256 - 1264

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Mabilleau G. et al, (2010), Bone, 46, S63 - S64

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Designed mutants of human farnesyl pyrophosphate synthase (FPPS) help to characterise the interactions of nitrogen-containing bisphosphonates with Tyrosine 204 and Phenylalanine 239 side-chain residues\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Tsoumpra M. et al, (2010), Bone, 46, S23 - S23

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Determination of the relative bone mineral-binding affinities of bisphosphonates by using hydroxyapatite-column chromatography combined with mass spectrometric analysis\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Duan X. et al, (2010), Bone, 46, S23 - S23

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n The Ability of Bisphosphonates and Their Analogues to Penetrate the Osteocyte Network is Dependent on Affinity for Bone\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Coxon F. et al, (2010), Bone, 46, S22 - S22

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n 2009 Santa Fe Bone symposium.\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Lewiecki EM. et al, (2010), J clin densitom, 13, 1 - 9

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }